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A B S T R A C T
Primary indicated prevention is reliant on accurate tools to predict the onset of psychosis. The gold
standard assessment for detecting individuals at clinical high risk (CHR-P) for psychosis in the UK and
many other countries is the Comprehensive Assessment for At Risk Mental States (CAARMS). While the
prognostic accuracy of CHR-P instruments has been assessed in general, this is the ﬁrst study to
speciﬁcally analyse that of the CAARMS. As such, the CAARMS was used as the index test, with the
reference index being psychosis onset within 2 years. Six independent studies were analysed using
MIDAS (STATA 14), with a total of 1876 help-seeking subjects referred to high risk services (CHR-P+:
n = 892; CHR-P–: n = 984). Area under the curve (AUC), summary receiver operating characteristic curves
(SROC), quality assessment, likelihood ratios, and probability modiﬁed plots were computed, along with
sensitivity analyses and meta-regressions. The current meta-analysis conﬁrmed that the 2-year
prognostic accuracy of the CAARMS is only acceptable (AUC = 0.79 95% CI: 0.75–0.83) and not
outstanding as previously reported. In particular, speciﬁcity was poor. Sensitivity of the CAARMS is
inferior compared to the SIPS, while speciﬁcity is comparably low. However, due to the difﬁculties in
performing these types of studies, power in this meta-analysis was low. These results indicate that
reﬁning and improving the prognostic accuracy of the CAARMS should be the mainstream area of
research for the next era. Avenues of prediction improvement are critically discussed and presented to
better beneﬁt patients and improve outcomes of ﬁrst episode psychosis.
C 2017 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
Contents lists available at ScienceDirect
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Psychosis is a severe psychiatric condition and there is limited
evidence that treatments are successful in improving patients’
functioning once the disorder is established [1]. Intervening in the
earlier phases is therefore the only viable possibility to substan-
tially alter the course of the disorder [2,3]. Within early
intervention, a key focus for improving the outcome has been
primary indicated prevention [2,4,5]. Primary indicated prevention
allows for early intervention for those at clinical high risk of* Corresponding author.
E-mail address: dominic.a.oliver@kcl.ac.uk (D. Oliver).
https://doi.org/10.1016/j.eurpsy.2017.10.001
0924-9338/C 2017 The Authors. Published by Elsevier Masson SAS. This is an open accdeveloping psychosis (CHR-P), with greater scope for improving
outcomes. To do this effectively, the ﬁrst necessary step is to reach
an accurate, robust prognostic identiﬁcation of individuals
meeting CHR-P criteria who will subsequently develop psychosis
or not. Ideally, all subjects who will actually develop psychosis
should be classiﬁed as ‘‘at risk’’ (CHR-P+) while those not
developing an established psychosis should be classiﬁed as ‘‘not
at risk’’ (CHR-P–). These key concepts involved in prognostic
reasoning in the CHR-P have been detailed and presented in a
recent paper by our group [6].
Prognostic prediction is used in many branches of medicine to
identify individuals who may develop a particular disease [7]. For
example, fasting glucose, oral glucose tolerance test and glycatedess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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developing diabetes (pre-diabetes or intermediate hyperglycae-
mia) [8] and systolic blood pressure and ratio of total serum
cholesterol to high density lipoprotein cholesterol levels are used
to detect individuals at high risk for developing cardiovascular
disease [9]. However, unlike these other ﬁelds, there are no
biological tests to assess the risk of developing mental disorders
[10], which is instead reliant on semi-structured CHR-P psycho-
metric interviews, such as the CAARMS (Comprehensive Assess-
ment for At Risk Mental States) [11]. Recently, the CAARMS has
become the mainstream tool to detect CHR-P individuals in the UK,
recommended by international bodies, such as NICE [12]. There-
fore, understanding its exact psychometric properties is of
paramount clinical relevance. The CAARMS shows excellent
inter-rater reliability when performed by trained raters (0.85)
[13]. However, its prognostic accuracy is uncertain. A recent meta-
analysis by our lab [14] investigated the prognostic accuracy of
CHR-P instruments, showing generally excellent prognostic
performance of these instruments. However, CHR-P tools were
grouped together including the CAARMS [11], the SIPS (Structured
Interview for Prodromal Syndromes) [15] and the SPI-A (Schizo-
phrenia Proneness Instrument-Adult Version) [16]. This was due to
the fact that there were not enough studies contributing data to
assess the meta-analytical prognostic accuracy of the CAARMS
speciﬁcally. Given the marked differences between the CAARMS
and other CHR-P instruments [17], in particular with respect to the
functional deterioration criterion [18], it is possible that the
previously reported meta-analytical prognostic accuracy is not
completely accurate. In addition, the previous meta-analysis
combined multiple follow-up time points, and even though
meta-regressions of this variable found no signiﬁcant effect,
validity of the prognostic accuracy results would be improved by
using a more deﬁned and consistent follow-up time [14].
The current study tackles these caveats and advances knowl-
edge in the psychometric properties of the CAARMS. We capitalize
on recently published CAARMS studies reporting useful and
innovative meta-analytical data to conduct a meta-analytical
prognostic accuracy analysis of the CAARMS at two-year follow-up.
This is the period of time during which most transitions to
psychosis occur [19]. The results will hopefully support the
reﬁnement of psychosis prediction and therefore facilitate
indicated primary prevention in CHR-P individuals.
2. Methods
2.1. Search strategy
Two investigators (DO, PFP) conducted a two-step literature
search. At a ﬁrst step, the Web of Knowledge database was
searched, incorporating both the Web of Science and Medline. The
search was extended until August 2017, only including abstracts in
English. The electronic research adopted several combinations of
the following keywords: ‘‘at risk mental state’’, ‘‘psychosis risk’’,
‘‘prodrome’’, ‘‘prodromal psychosis’’, ‘‘ultra-high risk’’, ‘‘high risk’’,
‘‘help-seeking’’, ‘‘diagnostic accuracy’’, ‘‘sensitivity’’, ‘‘speciﬁcity’’,
‘‘psychosis prediction’’, ‘‘psychosis onset’’. The second step
involved the use of Scopus to investigate citations of previous
systematic reviews on transition outcomes in CHR-P subjects and a
manual search of the reference lists of the retrieved articles.
Articles identiﬁed through these two steps were then screened
for the selection criteria on the basis of abstract reading. The
articles surviving this selection were assessed for eligibility on the
basis of full text reading. To achieve a high standard of reporting,
we adopted the Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) checklist [20].2.2. Selection criteria
Studies were eligible for inclusion if:
 they were reported in original articles, written in English;
 they had used the CAARMS (index test) in the same pool of
referrals;
 they had followed up both CHR-P+ and CHR-P– subjects for
psychosis onset (reference index) using established internation-
al diagnostic manuals (ICD or DSM);
 they had reported sufﬁcient prognostic accuracy data at 2-year
follow-up.
With respect to this last point, when data were not directly
presented, they were indirectly extracted from associated data.
Additionally, we contacted all corresponding authors to request
additional data when needed.
We excluded:
 abstracts, reviews, articles in a language other than English;
 studies in which interviews were not conducted in the same
pool of referrals or that used an external CHR-P group of healthy
controls;
 studies with overlapping datasets.
In case of multiple publications deriving from the same study
population, we selected the article reporting the largest and most
recent data set. The literature search was summarized according to
PRISMA guidelines [21].
2.3. Recorded variables
Data extraction was independently performed by two investi-
gators (DO, PFP). Data included author, year of publication,
characteristics of subject samples (baseline sample sizes, mean
age and age range, proportion of females), diagnostic criteria used
at follow-ups to assess the psychotic outcome, prognostic accuracy
data (number of true and false positives, true and false negatives or
associated data) and quality assessment conducted with the
Quality Assessment of Diagnostic Accuracy Studies (QUADAS)
checklist [22].
2.4. Statistical analysis
The statistical analysis followed the Cochrane Guidelines for
Systematic Reviews of Diagnostic Test Accuracy, Version 1.0 [23]
and the Methods Guide for Authors of Systematic Reviews of
Medical Tests by the Agency for Healthcare Research and Quality
(chapter 8) [24]. Evaluating test accuracy requires knowledge of
two quantities: the test’s sensitivity (Se) and speciﬁcity (Sp). Meta-
analysis methods for diagnostic test accuracy thus have to deal
with two summary statistics simultaneously rather than one
[23]. Methods for undertaking analyses, which account for both Se
and Sp, the relationship between them, and the heterogeneity in
test accuracy, require ﬁtting advanced hierarchical random effects
models [23].
For each study, we constructed a two-by-two table, which
included true positive, false positive, true negative, and false
negative values. The baseline sample size was conservatively used
as the base reference.
Data were then analysed with MIDAS (Meta-analytical Integra-
tion of Diagnostic Accuracy Studies) [25], a comprehensive program
of statistical and graphical routines for undertaking meta-analysis of
diagnostic/prognostic test performance in STATA 14 software
[26]. The index tests of CHR-P status (CHR-P+ or CHR-P–) and
reference tests of transition to psychosis according to international
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mous.
Primary data synthesis was performed within the bivariate
mixed-effects regression framework for the logit transforms of Se
and Sp. In addition to accounting for study size, the bivariate model
estimates and incorporates the intrinsic negative correlation that
may arise between Se and Sp within studies (threshold effect) [27],
as a result of differences in the test threshold between studies
[28]. The bivariate model allows for heterogeneity beyond chance
as a result of clinical and methodological differences between
studies [28].
We estimated the summary Se and Sp and the hierarchical
SROC (summary receiver operator characteristic) curves
[23,32]. A SROC graph across each predictor, with the y-axis
representing the predictor’s Se and the x-axis representing 1–
speciﬁcity, was used to plot a 95% conﬁdence region and a 95%
prediction region around the summary estimates to illustrate the
precision with which the summary values were estimated
(conﬁdence ellipse of a mean), and to show the amount of
between-study variation (prediction ellipse; the likely range of
values for a new study). We also estimated the AUC (area under
the curve). The AUC serves as a global measure of test
performance. Values in the range of 0.9–1 are considered
outstanding, between 0.8 and 0.9 are considered excellent,
between 0.7 and 0.8 are considered acceptable [29].
Heterogeneity across studies was assessed using the I2, with
values of 25%, 50% and 75% representing mild, moderate and
severe inconsistency, respectively [30]. Within MIDAS, forest
plots and heterogeneity statistics can be created for each test
performance parameter individually or may be displayed as
paired plots. Meta-regressions were used to examine the
inﬂuence of mean age, gender (% females), sample size, and
quality assessment (QUADAS) on meta-analytical estimates.
Furthermore, we investigated the prognostic accuracy difference
between CAARMS based studies and studies employing the SIPS,
as detected in the previous meta-analysis [14]. To control for
biases associated with imbalanced datasets [31], we further
tested the impact of the proportion of CHR-P+ subjects in the
overall samples. The meta-regressions were used if there was
substantial heterogeneity (I2 > 50%) [32] and when more than
10 studies were available.
Sensitivity analyses (i.e., exclusion of outliers and rerunning of
the model) were conducted to further explore heterogeneity. We
did not test publication bias [33], because no proven statistical
method exists for this type of meta-analysis [34].
In a second step, we employed the probability-modifying plot
to estimate the clinical or patient-relevant utility of the CAARMS in
subjects seeking help at CHR-P services.
The clinical utility was evaluated using the positive and
negative likelihood ratios (LR+ and LR–) to calculate post-test
probability (post-TP) based on Bayes’ theorem (with pre-test
probability, pre-PT, being the prevalence of the condition in the
target population), as follows: post-TP = LR  pre-TP/[(1 – pre-
TP) + (pre-TP  LR)] [27]. Speciﬁcally, the probability-modifying
plot [25] is a graphical sensitivity analysis of the test’s predictive
values across a baseline psychosis risk continuum in people
seeking help at CHR-P services. It depicts separate curves for
positive and negative tests and uses general summary statistics
(i.e., unconditional positive and negative predictive values,
NPV and PPV, which permit underlying psychosis risk heteroge-
neity) to evaluate the effect of the CHR-P assessment on
predictive values [35]. The pre-TP probability of psychosis
risk in subjects seeking help at early detection services was
computed in the current dataset as the proportion of subjects
developing psychosis on the total baseline sample (CHR-P+ plus
CHR-P–) [25].Statistical tests were two-sided and statistical signiﬁcance was
deﬁned as P values < 0.05.
3. Results
3.1. Database
The literature search produced 6 independent studies [36–41]
that met inclusion criteria with a total of 1876 subjects (CHR+:
n = 892; CHR–: n = 984) referred to clinical high risk services. The
dataset was balanced with CHR+ individuals composing 47.5% of
the total subjects. The characteristics of the studies are reported in
the Table 1 while the PRISMA diagram is depicted in Fig. 1. The
MOOSE checklist is reported in the eTable 1. The detailed QUADAS
assessment is reported in the eTable 2 and eFig. 1.
3.2. Prognostic accuracy of the CAARMS at 2-years
The summary meta-analytical estimate of Se at 2 years (0.86,
95% CI = 0.76–0.92) was outstanding with the 2-year AUC (0.79,
95% CI = 0.75–0.83) acceptable but the estimate of 2-year Sp (0.55,
95% CI = 0.48–0.63) was poor (Fig. 2). There was severe heteroge-
neity present in this analysis (I2 = 93.28%, 95% CI = 89.42–97.15%).
3.3. Clinical utility of the CAARMS at 2 years
The 2-year psychosis transition risk in the 1876 subjects was
0.09 (95% CI = 0.05–0.13). On the basis of the prior distribution, the
continuous relationship between pre-TP and post-TP probability is
summarized in Fig. 3. Being CHR-P+ was associated with a 0.16
(95% CI = 0.10–0.22) risk of developing psychosis within 2 years,
yet a small LR+ of just 1.9 (95% CI = 1.5–2.4) while being CHR-P–
was associated with a 0.03 (95% CI = 0.02–0.05) risk of transition to
psychosis with a moderate LR– of 0.25 (95% CI = 0.13–0.48).
3.4. Meta-regressions and sensitivity analyses
Sensitivity analysis suggested that one study [41] was
inﬂuential with a Cook’s distance > 1. While we hypothesised
this was due to the study reporting 0 false negatives, we were
unable to test the effect of false negatives through meta-regression
due to low number of studies. Similarly, we were unable to
perform meta-regressions for age, gender, QUADAS score or
sample size as there were fewer than 10 studies contributing
data. As indicated in the methods, we were able to perform a meta-
regression comparing the prognostic accuracy of the CAARMS vs.
that of the SIPS, using the studies reporting SIPS data [42–46] only
as identiﬁed in our previous study (n = 5, CHR+: n = 783; CHR–:
n = 360). As indicated in Fig. 4, Se was signiﬁcantly higher
(P < 0.001) for the SIPS (n = 5, mean = 0.95, 95% CI 0.91–0.99)
compared to the CAARMS (n = 6, mean = 0.87, 95% CI 0.79–0.96),
while Sp was comparably (P = 0.27) low in the SIPS (n = 5,
mean = 0.45, 95% CI = 0.38–0.53) and in the CAARMS (n = 6,
mean = 0.55, 95% CI 0.48–0.62).
4. Discussion
This is the ﬁrst meta-analysis speciﬁcally investigating the
prognostic accuracy of the CAARMS for the prediction of psychosis.
We found 6 studies that investigated prognostic accuracy of the
CAARMS at two-year follow-up, which contributed a relatively
large database of 1876 subjects overall, with 892 considered CHR-
P+ and 984 CHR-P–. Prognostic accuracy of the CAARMS in terms of
AUC was found to be only acceptable (0.79), mostly mediated by its
substantial ability to rule out psychosis (i.e. LR– was relatively
Table 1
Independent studies included in the meta-analysis (studies n = 6; 1876 subjects; CHR+: n = 892; CHR–: n = 984).
Study QUADAS score (14 = max);
exposure to antipsychotics at baseline
Psychosis diagnosis
(reference standard)
Age (mean  SD,
range)
Gender
(% females)
CHR-P+
(baseline)
CHR-P–
(baseline)
1. Yung et al., 2008 [39] 12; yes (N/A) CAARMS 18.1 (15–24) 51.0 119 173
2. Lee et al., 2013 [41]a 13; no DSM-IV 21.6  3.5 (14–29) 39.9 173 494
3. Fusar-Poli et al., 2017 [36] 11.5 ICD-10 23  5.4 (12–44) 43.8 411 299
4. Francesconi et al., 2017 [37] 12 CAARMS 24.3  3.5 47.0 54 62
5. Kotlicka-Antczak et al., 2015 [40]a 11.5; yes (10.2%) ICD-10 19.05  3.6 (15–29) 51.1 (c) 94 33
6. Spada et al., 2015 [38] 11; no DSM-IV 15.8  1.7 (12–17) 47.5 22 18
CAARMS: Comprehensive Assessment of At Risk Mental States; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders; ICD-10: International Classiﬁcation of
Diseases Tenth Revision; N/A: Not available.
a Updated follow-up data provided by the authors.
Fig. 1. PRISMA ﬂow chart.
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psychosis (i.e. LR+ was small and Sp was poor). While prognostic
accuracy was overall acceptable, this study indicates that reﬁning
the prediction of outcomes should be the key priority of future
research in this ﬁeld.
The primary aim of the study was to synthesize available data
for the prognostic accuracy of the CAARMS in determining
psychosis risk 2 years after young help-seeking subjects presented
to CHR-P services. As noted in the introduction, our recent meta-
analysis [14] looked into the prognostic accuracy of CHR-P
instruments as a collective. The current study advances knowledge
indicating that the exact prognostic accuracy of the CAARMS alone
is weaker (0.79) than the overall value previously observed when
the CHR-P instruments were pooled together (0.90). Although not
as outstanding as before, the AUC value here reported is stillconsidered to be acceptable for a diagnostic test and is comparable
to other prognostic tools used in different areas of medicine, such
as the AUC = 0.76 attributed to the Cambridge risk score for pre-
diabetes [47]. In a similar fashion, we found that the Se (0.86) of the
CAARMS alone was less impressive than the Se (0.96) of CHR-P
instruments assessed in the previous meta-analysis. Interestingly,
there was an apparent minor increase in Sp (0.55 for CAARMS alone
compared to 0.47 for CHR-P instruments generally) [14]. The lower
AUC compared to the previous general estimate may reﬂect
profound operationalization differences between the CAARMS and
the other CHR-P instruments. For example, a comparative analysis
between the CAARMS and the SIPS conﬁrmed caseness discre-
pancies between the two instruments [17], mostly due to different
deﬁnition of brief limited intermittent psychotic cases, ascertain-
ment of comorbidities [17] and of functional level at intake [18]. To
Fig. 2. Meta-analytical summary receiver operating characteristic (SROC) curve of
CAARMS assessment. SENS – sensitivity, SPEC – speciﬁcity, AUC – area under the
curve, 1 – Yung et al., 2008 [39], 2 – Lee et al., 2013 [12], 3 – Fusar-Poli et al., 2017
[2], 4 – Francesconi et al., 2017 [37], 5 – Kotlicka-Antczak et al., 2015 [40], 6 – Spada
et al., 2016 [38].
Fig. 3. Meta-analytical probability-modifying plot, illustrating the relationship
between the pre-test probability (pre-TP) and post-test probability (post-TP) i.e.
psychosis risk in help-seeking subjects following CAARMS assessment, computed as
the likelihood of a positive (above diagonal line; LR+) or negative (below diagonal
line; LR–) test result over the pre-TP between 0 and 1.
Fig. 4. Meta-regression analyses comparing at meta-analytical level the 2-year
sensitivity and speciﬁcity of the CAARMS vs. SIPS for the prediction of psychosis.
SIPS data taken from [14].
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performance, in the current study, we performed the ﬁrst
meta-analytical comparison of Se and Sp across the CAARMS
and SIPS, using previously published SIPS data [14]. We found that
Se was higher in the SIPS compared to the CAARMS, while there
were no substantial differences in Sp. Overall, it is unlikely that
these differences may account for signiﬁcant differences in the
positive predictive values of the two instruments, as conﬁrmed by
previous meta-analyses in CHR-P+ samples [18].
In a second step, we estimated the clinical utility of the
CAARMS. As previously reported by our lab, clinical utility is not
static, instead reliant on the underlying pre-test risk in any given
population [49–51]. We found that being classiﬁed as CHR+ by the
CAARMS is associated with a 16.4% risk of developing psychosis
within 2 years, which is lower than the 29.1% 2-year transition
risk previously reported [52]. This was driven by a small LR+ (1.9),similar to the LR+ seen previously (1.82) [14]. CHR– individuals
had 3.38% 2-year transition rate and this was driven by a
moderate LR– (0.25), which was not as large as the LR– for CHR
assessments as a whole (0.09) [14]. These ﬁndings taken
altogether indicate that the acceptable prognostic accuracy is
due to an imbalance between Se and Sp and LR+ and LR–, with the
CAARMS being a valuable tool to correctly identify individuals
who will develop psychosis however showing only modest ability
to identify those who will not.
On a pragmatic level, the results of this meta-analysis show that
the only acceptable prognostic accuracy of the CAARMS needs
improving through a reﬁned assessment of psychosis risk. An
improved detection of individuals who will transition would lead to
improved clinical and research opportunities. For example, a greater
proportion of true positives would lead to more efﬁcient primary
indicated prevention as well as a more homogenous CHR-P group
[48,53] for developing putative treatments. This manuscript has the
clinical potential to be the reference point for reﬁning future
versions of the CAARMS or for the development of reﬁned
prognostic tools and assessments. To improve prediction of
psychosis, it seems necessary to tailor it on an individual level.
To date, the CAARMS has just considered CHR-P+ individuals as
belonging to a whole group. However, it is now clear that such an
assumption is incorrect, given the profound difference in level of
psychosis risk observed across different CHR-P+ subgroups
[48,53]. Furthermore, to date, psychosis prediction has been limited
to the assessment and rating of CHR-P symptoms and signs.
However, it is evident that these are only epiphenomena of
underlying neurobiological and psychological processes that may
characterize the onset of psychosis in vulnerable individuals.
Research evidence in the ﬁeld of risk and protective factors
associated with an impending vulnerability to psychosis has
accumulated over the past few decades and only recently has it
been systematically assessed. In a recent large-scale meta-analysis,
our lab has stratiﬁed the level of evidence for associations of several
risk or protective factors and established psychotic disorders
[54]. This study may lay the groundwork for investigating how
speciﬁc risk or protective factors accumulate in CHR-P+ individuals
explaining their increased liability to develop psychosis. In a ﬁrst
attempt by our lab [55], we reviewed forty-four studies encom-
passing 170 independent datasets and 54 risk/protective factors in
CHR-P+ individuals. We showed that CHR-P+ individuals were more
likely to show obstetric complications, tobacco use, physical
inactivity, childhood trauma/emotional abuse/physical neglect,
high perceived stress, childhood and adolescent low functioning,
affective comorbidities, male gender, single status, unemployment
and low educational level as compared to controls. The differential
accumulation of these factors in each CHR-P+ individuals are likely
to account for the different outcomes observed in these samples,
such as psychosis onset, persistence of CHR-P+ features or
remission. A reﬁnement of psychosis prediction in these samples
would inevitably require a careful investigation of these factors
beyond the rating of severity and frequency of CHR-P+ symptoms as
currently required by the CAARMS.
D. Oliver et al. / European Psychiatry 49 (2018) 62–68 674.1. Limitations
Some limitations of this meta-analysis need to be acknowl-
edged. Firstly, only 6 studies were able to be synthesised for this
meta-analysis, and although supplying a healthy number of
subjects, power could be questioned. Another limitation of our
meta-analysis is the small sample size. However, conducting
longitudinal studies in individuals assessed for a CHR-P state but
not meeting intake criteria is logistically challenging and therefore
only a few studies are currently available. Secondly, heterogeneity
was very high and this could potentially have been reduced
through a greater pool of studies. Thirdly, this heterogeneity
remains unexplained as we were unable to perform meta-
regressions because there were not enough studies.
5. Conclusion
The 2-year meta-analytical prognostic accuracy of the CAARMS
in predicting psychosis is only acceptable. A reﬁned prediction of
psychosis risk is necessary to advance clinical research in this area.
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